Notícias

AMN Healthcare is poised for growth as staffing demand rebounds, MSP penetration expands and tech-enabled workforce solutions broaden its reach.

NYXH initiates its U.S. BREATHE study with the first Genio implant, advancing long-term clinical evidence following FDA approval.

PHG broadens women's health ultrasound portfolio with the eV14-2v, offering enhanced imaging, a lighter design and remote collaboration.

NVCR says a cyber incident exposed limited patient and contact data, but devices stayed secure and operations remained fully functional.

Generation Investment Management, an investment management firm, released its “Global Equity Strategy” second quarter 2026 investor letter. The letter can be downloaded here. The letter discusses the challenges of AI-driven market concentration and emphasizes the potential for long-term investors. It notes that the best companies are currently underperforming due to market returns being concentrated in […]

How West Pharmaceutical Services stock has been performing West Pharmaceutical Services (WST) has drawn investor attention after recent share price moves, with the stock closing at US$339.97 on 3 September 2026. The company shows mixed returns over different periods, including gains over the past year alongside shorter term pullbacks. For West Pharmaceutical Services, the recent 1-day share price decline of 0.81% and 3.15% share price pullback over 30 days sit against a much stronger...

Cencora's specialty momentum, OneOncology growth and GLP-1 volumes offer upside, but drug-price cuts and MWI risks cloud its outlook.

HQY's growth is driven by rising HSA assets and AI-led efficiencies, while cybersecurity risks remain a key concern.

PHG's AI-powered 3D Auto CFQ shows stronger agreement with cardiac MRI than 2D PISA, supporting its cardiovascular ultrasound strategy.

NPCE's RNS adoption, reimbursement gains, referral expansion and AI tools support growth, while IGE delays and higher spending pressure profitability.

COR launches CGT Enablement to help health systems build and scale cell and gene therapy programs with financial, operational and access support.

VEEV's strong Q2 results, Vault CRM migrations and AI expansion support growth, while market saturation remains a key concern.

SYK's FDA-cleared SportSuite Vision brings Apple Vision Pro into hip arthroscopy, strengthening its digital surgery push and Sports Medicine portfolio.

Fresenius Medical's improving profitability, 5008X rollout and value-based care gains offer support despite volume and reimbursement risks.

HIMS has entered the second half of 2026 with weight-loss, international and AI momentum, but margin pressure and FDA uncertainty remain.

ENOV is set to acquire eCential Robotics to expand into orthopedic surgical robotics, though the deal is expected to pressure 2027 margins.

MMSI's broad portfolio, R&D investments and WRAPSODY opportunity support growth, while tariffs, China pressure and competition remain risks.

GE HealthCare's Photonova Spectra gains CE Mark, expanding access to its Deep Silicon photon-counting CT technology across Europe and other CE markets.

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.

Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with competition, ranging from giants with vast resources to agile upstarts eager to disrupt the status quo.

SYK's planned ZuriMED acquisition adds the FiberLocker System, aiming to strengthen its shoulder portfolio and rotator cuff care capabilities.

10x Genomics wins a $4.8M patent verdict against Parse, strengthening its IP position as it seeks added damages and a U.S. injunction.

GEHC expands its Vivid cardiovascular ultrasound portfolio with three systems featuring AI tools and cSound imaging for varied care settings.

CVRX secures Devoted Health Medicare Advantage coverage for Barostim, expanding reimbursement access to about 466,000 members across 29 states.

Align Technology (ALGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

NTRA teams with Angiex to use Signatera in a Phase 1 AGX101 trial, aiming to track ctDNA and deepen insights into treatment response.

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 24.9% over the past six months, topping the S&P 500 by 13.3 percentage points.

VEEV's Q2 fiscal 2027 earnings and revenues top estimates, while strong Vault CRM momentum and a raised full-year outlook drive shares higher.

MCK's $2.25B Precision Medicine Group deal aims to expand clinical research and commercialization services in oncology and multispecialty care.

Are Wall Street analysts favoring West Pharmaceutical’s stock now as GLP-1 drugs gain prominence?